fatty acid oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-29. Anything still debated is marked as such rather than presented as settled.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | GW501516; GW-1516; endurobol | GW501516 is the research code |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator |
| Molecular formula | C21H18F3NO3S2 | Established chemical formula |
| Molar mass | 453.5 g/mol | Calculated from the formula |
| Regulatory status | Prohibited in sport; not approved as medicine | Status varies by country |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Humans can experience all of the above-mentioned varieties of pair bonds. These bonds can be temporary or last a lifetime. They also engage in social pair bonding, where two form a close relationship that does not involve sex. Like in other vertebrates, pair bonds are created by a combination of social interaction and biological factors including neurotransmitters like oxytocin, vasopressin, and dopamine. Pair bonds are a biological phenomenon and are not equivalent to the human social institution of marriage. Married couples are not necessarily pair bonded. Marriage may be a consequence of pair bonding and vice versa. One of the functions of romantic love is pair bonding.
Adriaens, D. and Verraes, W. (1997). Ontogeny of the maxillary barbel muscles in Clarias gariepinus (Siluroidei: Clariidae), with some notes on the palatine-maxillary mechanism. Journal of Zoology (London) 241, 117–133. Bailey, D.M. , Wagner, H.J., Jamieson, A.J., Ross, M.F. and Priede, I.G. (2007) A taste of the deep-sea: The roles of gustatory and tactile searching behaviour in the grenadier fish Coryphaenoides armatus. Deep-Sea Research Part I: Oceanographic Research Papers, 54(1), pp. 99–108. (doi:10.1016/j.dsr.2006.10.005) de Freitas Barros Neto, L., Frigo, R. G., Gavilan, S. A., de Moura, S. A. B., & Lima, S. M. Q. (2020). Barbel development associated to aquatic surface respiration in Triportheus signatus (Characiformes: Triportheidae) from the semiarid Caatinga rivers. Environmental Biology of Fishes, 103(1), 89–98. https://doi.org/10.1007/s10641-019-00935-x Eakin, R. R., Eastman, J. T. and Vacchi, M. (2006). Sexual dimorphism and mental barbel structure in the South Georgia plunderfish Artedidraco mirus (Perciformes : Notothenioidei : Artedidraconidae). Polar Biology 30, 45–52. Fadaee, B., Pourkazemi, M., Tavakoli, M., Joushideh, H., Khoshghalb, M. R. B., Hosseini, M. R. and Abdulhay, H. (2006). Tagging and tracking juvenile sturgeons in shallow waters of the Caspian Sea (less than 10 m depth) using CWT (Coded Wire Tags) and barbel incision. Journal of Applied Ichthyology 22, 160–165. Fox, H. (1999). Barbels and barbel-like tentacular structures in sub-mammalian vertebrates: A review. Hydrobiologia 403, 153–193. Grover-Johnson, N. and Farbman, A. (1976).
== Industry and Research Community == Commercial products and companies based on aptamers include the drug Macugen (pegaptanib) and the clinical diagnostic company SomaLogic. The International Society on Aptamers (INSOAP), a professional society for the aptamer research community, publishes a journal devoted to the topic, Aptamers. Apta-index is a current database cataloging and simplifying the ordering process for over 700 aptamers.
The ability to purify DNA from a sample is important for many modern biotechnology processes. However, samples often contain nucleases that degrade the target DNA before it can be purified. It has been shown that DNA fragments will partition into the light phase of a polymer–salt separation system. If ligands known to bind and deactivate nucleases are incorporated into the polymer phase, the nucleases will then partition into the heavy phase and be deactivated. Thus, this polymer–salt system is a useful tool for purifying DNA from a sample while simultaneously protecting it from nucleases.
NAD-dependent deacetylase sirtuin-3, mitochondrial also known as SIRT3 is a protein that in humans is encoded by the SIRT3 gene. SIRT3 is member of the mammalian sirtuin family of proteins, which are homologs to the yeast Sir2 protein. SIRT3 exhibits NAD+-dependent deacetylase activity. Members of the sirtuin family are characterized by a sirtuin core domain and grouped into four classes, and the protein encoded by this gene is included in class I of the sirtuin family. The human sirtuins have a range of molecular functions and have emerged as important proteins in aging, stress resistance, and metabolic regulation. Yeast sirtuin proteins are known to regulate epigenetic gene silencing and suppress recombination of rDNA. In addition to protein deacetylation, studies have shown that the human sirtuins may also function as intracellular regulatory proteins with mono ADP ribosyltransferase activity.
Sources: en.wikipedia.org
==== Korean War ==== Coordination between development assistance and the Marshall Plan was tightened in response to the 1950–51 war in Korea. In October 1951 Congress passed the Mutual Security Act, creating the Mutual Security Agency (MSA), which reported directly to the President and supervised both civilian and military assistance. MSA increased the emphasis on large-scale financial assistance to U.S. allies, which was provided as civilian "economic assistance" but was intended to help the allies to make greater military efforts and was therefore often called "defense support". The Mutual Security Agency absorbed the Marshall Plan (the ECA), which otherwise had been scheduled to end in 1952. The Technical Cooperation Administration remained a semi-autonomous agency in the State Department to administer Point Four, but after 1951 under the supervision of MSA. Under this coordinated approach, the policy was adopted that ECA and TCA would not both operate in the same country ("one country – one agency"). Accordingly, each agency transferred programs to the other and closed down in some countries. For example, in Indonesia and Burma, ECA closed its financial-assistance programs, while TCA initiated technical assistance.
== Name and discovery == The name Coomassie was adopted at the end of the 19th century as a trade name by the Blackley-based dye manufacturer Levinstein Ltd, in marketing a range of acid wool dyes. In 1896 during the Fourth Anglo–Ashanti War, British forces had occupied the town of Coomassie (modern-day Kumasi in Ghana). In 1918 Levinstein Ltd became part of British Dyestuffs, which in 1926 became part of Imperial Chemical Industries. Although ICI still owns the Coomassie trademark, the company no longer manufactures the dyes. The blue disulfonated triphenylmethane dyes were first produced in 1913 by Max Weiler, who was based in Elberfeld, Germany. Various patents were subsequently taken out on the organic synthesis. Papers published in biochemistry journals frequently refer to these dyes simply as "Coomassie" without specifying which dye was used. In fact, the Colour Index lists over 40 dyes with "Coomassie" in their name. There are also other Coomassie "blue" dyes. For example, the Merck Index (10th edition) lists Coomassie Blue RL (Acid Blue 92, C.I. 13390), which has a completely different structure.
Biden and Trump agreed to hold debates on CNN on June 27 and ABC News on September 10. Biden and Trump debated on June 27, 2024, in Atlanta, Georgia. After Biden suspended his re-election campaign on July 21, 2024, Harris became the Democratic nominee and debated Trump on September 10, 2024, in Philadelphia, Pennsylvania.
The toxic action of mHTT may manifest and produce the HD pathology through multiple cellular changes. In its mutant (polyglutamine expanded) form, the protein is more prone to cleavage that creates shorter fragments containing the polyglutamine expansion. These protein fragments have a propensity to undergo misfolding and aggregation, yielding fibrillar aggregates in which non-native polyglutamine β-strands from multiple proteins are bonded together by hydrogen bonds. These aggregates share the same fundamental cross-beta amyloid architecture seen in other protein deposition diseases. The aggregates are covered on their surface with a 'fuzzy coat' that contains non-polyglutamine parts of the protein, as illustrated in a published structural model shown above. Over time, the aggregates accumulate to form inclusion bodies within cells, ultimately interfering with neuronal function. Inclusion bodies have been found in both the cell nucleus and cytoplasm. Inclusion bodies in cells of the brain are one of the earliest pathological changes, and some experiments have found that they can be toxic for the cell, but other experiments have shown that they may form as part of the body's defense mechanism and help protect cells. Several pathways by which mHTT may cause cell death have been identified.
The long bones are those that are longer than they are wide. They are one of five types of bones: long, short, flat, irregular and sesamoid. Long bones, especially the femur and tibia, are subjected to most of the load during daily activities and they are crucial for skeletal mobility. They grow primarily by elongation of the diaphysis, with an epiphysis at each end of the growing bone. The ends of epiphyses are covered with hyaline cartilage ("articular cartilage"). The longitudinal growth of long bones is a result of endochondral ossification at the epiphyseal plate. Bone growth in length is stimulated by the production of growth hormone (GH), a secretion of the anterior lobe of the pituitary gland. The long bone category includes the femora, tibiae, and fibulae of the legs; the humeri, radii, and ulnae of the arms; metacarpals and metatarsals of the hands and feet, the phalanges of the fingers and toes, and the clavicles or collar bones. The long bones of the human leg make up nearly half of adult height. The other primary skeletal component of height are the vertebrae and skull. The outside of the bone consists of a layer of connective tissue called the periosteum. Additionally, the outer shell of the long bone is compact bone, then a deeper layer of cancellous bone (spongy bone) which contains in the medullary cavity the bone marrow.
Sources: en.wikipedia.org
No. Cardarine is GW501516, a PPARδ agonist, while SARMs act on androgen receptors. The two classes are often grouped in informal discussions despite different mechanisms.
No. It has no approved medical indication in any country. Regulatory agencies have not cleared it for treatment or prevention of any condition.
Early clinical work stopped after rodent carcinogenicity findings. Those animal results raised concerns about long-term human risk, although direct human evidence is lacking. The human relevance of the tumors remains an open scientific question.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.